Wealth Management Strategies Inc. Invests $946,000 in Eli Lilly and Company (NYSE:LLY)

Wealth Management Strategies Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,226 shares of the company's stock, valued at approximately $946,000. Eli Lilly and Company makes up 0.7% of Wealth Management Strategies Inc.'s holdings, making the stock its 16th biggest holding.

Several other institutional investors have also bought and sold shares of LLY. FPC Investment Advisory Inc. boosted its holdings in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after acquiring an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at $48,000. Compass Financial Services Inc bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $50,000. Fiduciary Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $58,000. Finally, Bellwether Advisors LLC purchased a new stake in Eli Lilly and Company in the fourth quarter valued at about $66,000. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their target price for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. UBS Group reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 0.2%

NYSE:LLY traded down $1.21 on Monday, reaching $713.99. The company's stock had a trading volume of 2,631,160 shares, compared to its average volume of 3,622,393. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The stock has a 50 day moving average price of $789.29 and a 200 day moving average price of $803.22. The firm has a market cap of $676.67 billion, a price-to-earnings ratio of 60.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.58 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.84%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.